NovoCure Files 8-K for Reg FD and Financials
Ticker: NVCR · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, financial-reporting, regulation-fd
Related Tickers: NVCR
TL;DR
NovoCure filed an 8-K on 3/27 for Reg FD & financials. All good.
AI Summary
NovoCure Limited filed an 8-K on March 27, 2024, to report on Regulation FD disclosures and financial statements. The filing details the company's principal executive offices located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF, with a principal business phone number of +44 (0) 15 3475 6700. The company was formerly known as Novocure Ltd, with a name change effective June 15, 2015.
Why It Matters
This 8-K filing provides essential corporate information and disclosures, which are crucial for investors to stay informed about NovoCure's regulatory compliance and financial reporting status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- NovoCure Limited (company) — Registrant
- Novocure Ltd (company) — Former company name
- March 27, 2024 (date) — Filing date
- No. 4 The Forum, Grenville Street St. Helier Jersey JE2 4UF (location) — Principal Executive Offices
- +44 (0) 15 3475 6700 (phone_number) — Registrant's telephone number
- June 15, 2015 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for NovoCure Limited?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and financial statements, as indicated by the 'ITEM INFORMATION' section.
When was this 8-K report filed with the SEC?
The 8-K report was filed on March 27, 2024.
What is NovoCure Limited's principal executive office address?
NovoCure Limited's principal executive offices are located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
What was NovoCure Limited's former company name?
NovoCure Limited's former company name was Novocure Ltd.
On what date did NovoCure Limited's name change occur?
The date of the name change for NovoCure Limited was June 15, 2015.
Filing Stats: 863 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2024-03-27 07:00:15
Filing Documents
- nvcr-20240327.htm (8-K) — 27KB
- specialreportprmarch2024.htm (EX-99.1) — 17KB
- 0001645113-24-000009.txt ( ) — 174KB
- nvcr-20240327.xsd (EX-101.SCH) — 2KB
- nvcr-20240327_lab.xml (EX-101.LAB) — 21KB
- nvcr-20240327_pre.xml (EX-101.PRE) — 12KB
- nvcr-20240327_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On March 27, 2024 , NovoCure Limited (the "Company" or "Novocure"), issued a press release announcing that its phase 3 METIS clinical trial trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery (SRS).Preliminary analyses of key secondary endpoints (time to neurocognitive failure, overall survival, and radiological response rate) did not demonstrate statistical significance. Certain secondary endpoints showed positive trends in favor of treatment with TTFields therapy, including time to distant progression and quality of life. Full analysis of secondary endpoints is ongoing. Novocure intends to submit these data to regulatory authorities. Novocure also intends to publish these findings in a peer-reviewed scientific journal and share them at an upcoming scientific congress. METIS [NCT02831959] is a phase 3 trial of stereotactic radiosurgery with or without TTFields therapy for patients with 1-10 brain metastases from NSCLC. 298 adult patients were enrolled in the trial and randomized to receive either TTFields therapy with supportive care or supportive care alone following SRS. Supportive care consisted of, but was not limited to, treatment with steroids, anti-epileptic drugs, anticoagulants, pain control or nausea control medications. Patients in both arms of the study were eligible to receive systemic therapy for their NSCLC at the discretion of their treating physician. Patients with known tumor mutations for which targeted agents are available were excluded from the trial. The primary endpoint of the METIS trial is time to first intracranial progression, as measured from the date of first SRS treatment to
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated March 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: March 27, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer